Moderna Soars Another 9% as Piper Sandler Lifts Target to $305 on Raised Outlook

Moderna's stock rose 9% after Piper Sandler increased its price target to $305, citing strong Q3 results and a raised 2026 revenue outlook. The company's growth was driven by overseas COVID vaccine sales and government deals, while BioNTech and Pfizer saw declines. Piper's target also reflects optimism about Moderna's melanoma vaccine in development with Merck. Goldman Sachs maintained a Neutral rating with a $195 target.

Original reporting

finance.yahoo.com

Published Nov 9, 2026, 4:35 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 9, 2026, 4:51 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Moderna Soars Another 9% as Piper Sandler Lifts Target to $305 on Raised Outlook — source image — Source · finance.yahoo.com

Decision brief

The 30-second read

$MRNABullishHigh

Why it matters

Analyst upgrade and price target raise provide a clear catalyst for short‑term upside.

Market read

The news directly moves Moderna stock and may influence related biotech equities.

What to watch

Potential competition from other mRNA cancer vaccine programs and regulatory hurdles.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Moderna reported a Q3 beat driven by overseas COVID vaccine sales and announced a higher 2026 revenue outlook.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$MRNABullishHigh confidence

Context

Moderna shares jumped 9% after Piper Sandler raised its price target to $305, citing a stronger outlook and a melanoma vaccine partnership.

Expected impact

upward pressure as investors price in the higher target and melanoma vaccine potential

Evidence & confidence

Analyst upgrade with a substantial target increase and a double‑digit intraday move indicate fresh bullish sentiment.

Market effects

Sector

Biotech sector may see modest uplift as analyst confidence in vaccine pipelines rises.

Regional

U.S. biotech stocks could benefit from spillover of positive sentiment.

Global

Limited to investors focused on biotech and vaccine development.

Counterpoint

What could challenge this read

The target may be overly optimistic if melanoma vaccine timelines slip, risking a pullback.

Key entities

Company
Moderna
Biotech firm developing mRNA vaccines.
Analyst
Piper Sandler
Equity research firm that raised the price target.

Read at source ← All news

$MRNAHighAI 8/10

Why is Moderna (MRNA) stock soaring today

Moderna (MRNA) shares rose 6.4% after reporting Q3 2026 revenue of $1.3B, up 29% YoY, and raising full-year revenue growth forecast to 15-25%. The company also posted GAAP net income of $0.2B and EPS of 38 cents. The stock has gained 739% YTD, reaching a new 52-week high of $258.80.

finance.yahoo.comNov 10

$MRNAMed

Can Moderna's First Cancer Therapy Win FDA Approval in 2027?

Moderna and Merck aim to file for FDA approval of their cancer therapy, intismeran autogene, by year-end 2026, with a potential decision in 2027. The therapy showed positive results in a phase III study, reducing recurrence or death risk by 42%. Manufacturing and commercialization challenges remain, including patient-specific production and pricing. Moderna's shares have surged 760% year-to-date, trading at a premium P/S ratio of 38.88.

zacks.comNov 9

$MRNAMed

Piper Sandler maintains Moderna at Overweight, raises price target to $305 from $230

Piper Sandler raised its price target for Moderna to $305 from $230, citing a 20% upside from the Nov 6 close. Recent analyst targets range from $90 to $230.

tradingview.comNov 9

$MRNAHigh

Pressure in Washington, a rubber stamp in Ottawa? Canada first to approve Moderna's mRNA flu shots

Health Canada approved Moderna's mRNA flu vaccine, mFLUSIVA, and its mRNA flu-COVID combo shot, mCOFLU, for adults 50+. Canada is the first country to approve both. A former U.S. health official alleged political pressure influenced the FDA's approval, which is contested. Health Canada's review process and the lack of immediate rollout raise questions about the approval's basis and timing.

rebelnews.comNov 9

$MRNAMedAI 8/10

Piper Sandler raises Moderna stock price target on sales beat

Piper Sandler raised its price target on Moderna (MRNA) to $305 from $230, citing strong Q3 2026 sales and increased 2026 revenue guidance. The stock has risen 936% in the past year. Moderna reported Q3 2026 earnings of $0.38 per share, up from a loss of $0.51 per share a year ago, with revenue up 29% to $1.3 billion. The company is also advancing cancer research with Merck, targeting a 2027 approval for a melanoma treatment.

investing.comNov 9

$GSKLow

GSK, Moderna Settle Patent Dispute Over Moderna COVID, RSV Shots

GSK and Moderna settled patent disputes over Moderna's COVID-19 and RSV vaccines, granting cross-licenses with no payment obligations. Both companies filed to dismiss GSK's U.S. claims with prejudice. GSK had sued Moderna in 2024 over lipid nanoparticle technology, separately suing Pfizer and BioNTech earlier. The cases are part of broader patent disputes among COVID-19 vaccine developers.

claimsjournal.comNov 9